DELFI Diagnostics, Inc.
Liquid Biopsy
2 open roles Liquid Biopsy Baltimore, United States 153 employees $332M raised Est. 2019
DFJ Growth
Menlo Ventures
OrbiMed
Eli Lilly and Company
Point72
Foresite Capital
About DELFI Diagnostics, Inc.
DELFI Diagnostics develops AI-powered liquid biopsy tests for early cancer detection and monitoring by analyzing DNA fragmentation patterns in blood.
DELFI Diagnostics, Inc. is listed on Rocketlist with 2 active roles. The company is categorized as Liquid Biopsy in MedTech. DELFI Diagnostics, Inc. is at Series B stage, with a B2B business model, headquartered in Baltimore, United States. DELFI Diagnostics, Inc. was founded in 2019 and has 153 employees. DELFI Diagnostics, Inc. has raised $332M. Active roles are refreshed daily from public hiring sources.